High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ling, Chen ^a   Bhukhai, Kanit ^b   Yin, Zifei ^a,c   Tan, Mengqun ^d   Yoder, Mervin C ^e   Leboulch, Philippe ^b   Payen, Emmanuel ^b   Srivastava, Arun ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d Central South University   (China)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN;

CELL CULTURE TECHNIQUE; CELL LINE; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE EDITING; GENE EXPRESSION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; REPORTER GENE; SPECIES DIFFERENCE; VIROLOGY;

CAPSID PROTEINS; CELL CULTURE TECHNIQUES; CELL LINE; DEPENDOVIRUS; GENE EDITING; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC;

EID: 84992058766     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35495     Document Type: Article

References (37)

1. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322 (2010).
2. Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823 (2009).
3. Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).
4. Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363, 355-364 (2010).
5. Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
6. DiGiusto, D. L. et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+ ) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2, 36ra43 (2010).
7. Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31, 397-405 (2013).
8. Johnston, J. M. et al. High-throughput screening identifies compounds that enhance lentiviral transduction. Gene Ther 21, 1008-1020 (2014).
9. Negre, O. et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther 15, 64-81 (2015).
10. Merten, O. W. et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22, 343-356 (2011).
11. Joglekar, A. V. et al. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther 21, 1705-1717 (2013).
12. Li, L. et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21, 1259-1269 (2013).
13. Braun, C. J. et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med 6, 227ra233 (2014).
14. Zhou, S. Z. et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 179, 1867-1875 (1994).
15. Ponnazhagan, S. et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 71, 8262-8267 (1997).
16. Chatterjee, S. et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adenoassociated virus vectors. Blood 93, 1882-1894 (1999).
17. Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105, 7827-7832 (2008).
18. Markusic, D. M. et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 18, 2048-2056 (2010).
19. Kauss, M. A. et al. Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum Gene Ther 21, 1129-1136 (2010).
20. Song, L. et al. Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy 15, 986-998 (2013).
21. Song, L. et al. High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PLoS One 8, e58757 (2013).
22. Srivastava, A. Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector. Hum Gene Ther 27, 1-6 (2016).
23. Wang, L. N. et al. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J Integr Med 12, 20-34 (2014).
24. Smith, L. J. et al. Gene transfer properties and structural modeling of human stem cell-derived AAV. Mol Ther 22, 1625-1634 (2014).
25. Zhang, Y. H. et al. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med 12, 483-494 (2014).
26. Aslanidi, G. V. et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS One 8, e59142 (2013).
27. Qing, K. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5, 71-77 (1999).
28. Weller, M. L. et al. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16, 662-664 (2010).
29. Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol (2015).
30. Schmidt, F. & Grimm, D. CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnol J 10, 258-272 (2015).
31. Gammon, K. Gene therapy: editorial control. Nature 515, S11-S13 (2014).
32. Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 7, 307ra156 (2015).
33. Wang, J. et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 33, 1256-1263 (2015).
34. De Ravin, S. S. et al. Targeted gene addition in human CD34 hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 34, 424-431 (2016).
35. Ma, W. et al. A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Hum Gene Ther 22, 633-640 (2011).
36. Dong, B. et al. A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res 41, 6609-6617 (2013).
37. Wang, Q. et al. Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery. Hum Gene Ther Methods 25, 261-268 (2014).